Search

Fate Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

2.48 -3.88

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.45

Max

2.63

Galvenie mērījumi

By Trading Economics

Ienākumi

1.2M

-31M

Pārdošana

-70K

1.3M

EPS

-0.26

Peļņas marža

-2,402.848

Darbinieki

161

EBITDA

14M

-28M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+101.54% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 10. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

38M

291M

Iepriekšējā atvēršanas cena

6.36

Iepriekšējā slēgšanas cena

2.48

Ziņu noskaņojums

By Acuity

14%

86%

24 / 340 Rangs Healthcare

Fate Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. aug. 19:56 UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

2026. g. 4. aug. 20:07 UTC

News
Correlated Moves

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

2026. g. 3. aug. 23:01 UTC

News

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

2026. g. 29. jūl. 19:19 UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

2026. g. 28. jūl. 16:06 UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

2026. g. 27. jūl. 21:02 UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

2026. g. 24. jūl. 19:07 UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

2026. g. 23. jūl. 21:11 UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

2026. g. 22. jūl. 23:46 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

2026. g. 20. jūl. 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Salīdzinājums

Cenas izmaiņa

Fate Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

101.54% augšup

Prognoze 12 mēnešiem

Vidējais 5.24 USD  101.54%

Augstākais 8 USD

Zemākais 2.2 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Fate Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

5

Pirkt

4

Turēt

0

Pārdot

Noskaņojums

By Acuity

24 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat